Independent clinical trial site management organisation (SMO), Panthera Biopartners, has appointed Paul Smalley as finance director. Paul who has extensive experience working internationally and in conjunction with private equity brings knowledge from several business-to-business organisations. As a group finance director, he also brings expertise in IT, HR and logistics.
Panthera’s Chairman Professor John Lyon commented: “We are delighted that Paul has joined us as finance director. He has wide experience across sectors which will be very helpful in developing our business as we continue to expand our site network across the UK and overseas.”
Panthera which was only launched in 2019 will by the end of this year have extended its UK network to ten sites to become a major player in the UK. With its managements expertise in running clinical trials globally it is already in negotiation on extending its network overseas.”
Panthera is currently involved in running clinical trials on behalf of its clients in pharma and CROs including several COVID 19 studies as well as trials in oncology, NASH, neurology, and conditions treated in primary care.